ChiCTR2500097893 版本V1.0 版本创建时间2025/02/27 09:04:56 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500097893 

最近更新日期:

Date of Last Refreshed on:

2025-02-27 09:04:49 

注册时间:

Date of Registration:

2025-02-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

帕金森病患者眼动功能异常及其左旋多巴反应性的研究

Public title:

A study on abnormal eye movement function and levodopa responsiveness in Parkinson's disease patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

帕金森病患者眼动功能异常及其左旋多巴反应性的研究

Scientific title:

A study on abnormal eye movement function and levodopa responsiveness in Parkinson's disease patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘述廷 

研究负责人:

李晓红 

Applicant:

Liu Shuting 

Study leader:

Li Xiaohong 

申请注册联系人电话:

Applicant telephone:

+86 189 4083 6726

研究负责人电话:

Study leader's
telephone:

+86 152 4119 3017

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

694327382@qq.com

研究负责人电子邮件:

Study leader's E-mail:

xhlihh@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

大连市中山区三八广场8号

研究负责人通讯地址:

大连市中山区三八广场8号

Applicant address:

No. 8 Sanba Square, Zhongshan District, Dalian City

Study leader's address:

No. 8 Sanba Square, Zhongshan District, Dalian City

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

大连市友谊医院

Applicant's institution:

Dalian Friendship Hospital

研究负责人所在单位:

大连市友谊医院

Affiliation of the Leader:

Dalian Friendship Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

LL-2024-004

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

大连市友谊医院伦理委员会

Name of the ethic committee:

Dalian Friendship Hospital Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2024-04-15 00:00:00

伦理委员会联系人:

秦怡

Contact Name of the ethic committee:

Qin Yi

伦理委员会联系地址:

大连市中山区三八广场8号

Contact Address of the ethic committee:

No. 8 Sanba Square, Zhongshan District, Dalian City

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 182 4202 5656

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

大连市友谊医院

Primary sponsor:

Dalian Friendship Hospital

研究实施负责(组长)单位地址:

大连市中山区三八广场8号

Primary sponsor's address:

No. 8 Sanba Square, Zhongshan District, Dalian City

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

辽宁

市(区县):

大连

Country:

China

Province:

Liaoning

City:

Dalian

单位(医院):

大连市友谊医院

具体地址:

大连市中山区三八广场8号

Institution
hospital:

Dalian Friendship Hospital

Address:

No. 8 Sanba Square, Zhongshan District, Dalian City

经费或物资来源:

自筹

Source(s) of funding:

Raise independently

研究疾病:

帕金森病  

Target disease:

Parkinson's disease

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

探索 PD 患者眼动的变化同临床运动障碍症状的关系,及眼动对左旋多巴药物的反应性,为丰富 PD 临床表型数据、探索眼动在 PD 多巴反应性评估中的价值提供证据。  

Objectives of Study:

Exploring the relationship between changes in eye movement in PD patients and the reactivity of eye movement to levodopa drugs provide evidence to enrich the clinical phenotype data of PD and explore the value of eye movement in the evaluation of dopa responsiveness in PD

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

入组标准:病例组 60 名,符合国际帕金森病与运动障碍病协会(International Parkinson and Movement Disorder Society,MDS)临床确诊 PD 的诊断标准;Hoehn-Yahr 分期(H-Y 分期)1~3 期;年龄>18 岁;未行 DBS(脑起搏器植入术)手术;影像学资料(包括 CT 和 MRI)未发现颅内病变。对照组 40 名,来自社区或本院体检中心同期健康志愿者,无神经系统、精神疾病病史,神经系统体格检查未发现阳性体征。

Inclusion criteria

Enrollment criteria: 60 patients in the case group met the diagnostic criteria for clinically confirmed PD of the International Association of Parkinson's Disease and Movement Disorders (International Parkinson and Movement Disorder Society, MDS); Hoehn-Yahr stage (H-Y stage) stage 1 to 3; age> 18 years; no DBS (brain pacemaker implantation) surgery; no intracranial lesions in radiographic data (including CT and MRI). In the control group, 40 healthy volunteers from the community or the physical examination center of the hospital, had no history of neurological or psychiatric diseases, and found no positive signs on neurological physical examination.

排除标准:

病例组及对照组排除标准:严重认知障碍者(MMSE≤24 分);白内障、黄斑变性、青光眼等眼部疾病导致视觉障碍,中心视力<0.5;严重听力下降无法配合眼动检查;其他原因(头或眼眶外伤所致动眼神经损伤、肿瘤压迫动眼神经等)引起的眼球运动障碍;明显的头部震颤;癫痫发作史;其他不能配合量表测量及眼动检查者

Exclusion criteria:

The exclusion criteria for case group and control group were as follows: severe cognitive impairment (MMSE<=24); Visual impairment caused by cataract, macular degeneration, glaucoma and other eye diseases, with central visual acuity < 0.5; Severe hearing loss can not cooperate with eye movement examination;Ocular movement disorders caused by other causes (oculomotor nerve injury caused by head or orbital trauma, tumor compression of oculomotor nerve, etc.); Significant head tremor; A history of seizures; Others could not cooperate with the scale measurement and eye movement examination

研究实施时间:

Study execute time:

From 2024-04-15 00:00:00 To 2025-04-15 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-03-05 00:00:00 To 2025-04-15 00:00:00

干预措施:

Interventions:

组别:

帕金森病组

样本量:

60

Group:

Parkinson's Disease group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

对照组

样本量:

40

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

辽宁 

市(区县):

大连 

Country:

China

Province:

Liaoning

City:

Dalian

单位(医院):

大连市友谊医院 

单位级别:

三甲 

Institution
hospital:

Dalian Friendship Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

扫视潜伏期

指标类型:

主要指标

Outcome:

Saccadic latency

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

扫视速度

指标类型:

主要指标

Outcome:

Saccadic speed

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2025-02-27 09:04:49